Josting, Andreas, Mueller, Horst, Borchmann, Peter, Baars, Joke W., Metzner, Bernd ORCID: 0000-0002-1496-1377, Doehner, Hartmut, Aurer, Igor, Smardova, Lenka, Fischer, Thomas, Niederwieser, Dietger, Schaefer-Eckart, Kerstin, Schmitz, Norbert, Sureda, Anna, Glossmann, Jan, Diehl, Volker, DeJong, Daphne, Hansmann, Martin-Leo, Raemaekers, John and Engert, Andreas (2010). Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. J. Clin. Oncol., 28 (34). S. 5074 - 5081. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Full text not available from this repository.

Abstract

Purpose High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. Patients and Methods Patients with histologically confirmed, relapsed HL were treated with two cycles of dexamethasone, cytarabine, and cisplatin, and those without disease progression were randomly assigned. In the standard arm (A), patients received myeloablative therapy with carmustine, BEAM (carmustine, etoposide, cytarabine, and melphalan) followed by PBSCT. Patients in the experimental arm (B) also received sequential cyclophosphamide, methotrexate, and etoposide in high-doses before BEAM. Freedom from treatment failure (FFTF) was the primary end point. Remission rates, overall survival (OS), and toxicity of treatment were secondary end points. Results From a total of 284 patients included, 241 responding patients were randomly assigned after two cycles of dexamethasone, cytarabine, and cisplatinum. Patients treated in arm B had longer treatment duration and experienced more toxicity and protocol violations (P < .05). Mortality was similar in both arms (20% and 18%). With a median observation time of 42 months, there was no significant difference in terms of FFTF (P = .56) and OS (P = .82) between arms. FFTF at 3 years was 62% (95% CI, 56% to 68%) and OS was 80% (95% CI, 75% to 85%). Patients with stage IV, early relapse, multiple relapse, anemia, or B symptoms had a higher risk of recurrence (P < .001). Conclusion Compared with conventional high-dose chemotherapy, additional SHDCT is associated with more adverse effects and does not improve the prognosis of patients with relapsed HL. J Clin Oncol 28:5074-5080.(C) 2010 by American Society of Clinical Oncology

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Josting, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, HorstUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baars, Joke W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Metzner, BerndUNSPECIFIEDorcid.org/0000-0002-1496-1377UNSPECIFIED
Doehner, HartmutUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aurer, IgorUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Smardova, LenkaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Niederwieser, DietgerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaefer-Eckart, KerstinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmitz, NorbertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sureda, AnnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Glossmann, JanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Diehl, VolkerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
DeJong, DaphneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hansmann, Martin-LeoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Raemaekers, JohnUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-491659
DOI: 10.1200/JCO.2010.30.5771
Journal or Publication Title: J. Clin. Oncol.
Volume: 28
Number: 34
Page Range: S. 5074 - 5081
Date: 2010
Publisher: AMER SOC CLINICAL ONCOLOGY
Place of Publication: ALEXANDRIA
ISSN: 1527-7755
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; COLONY-STIMULATING FACTOR; SEQUENTIAL CHEMORADIOTHERAPY; COMBINATION CHEMOTHERAPY; PROGNOSTIC-FACTORS; SALVAGE TREATMENT; RANDOMIZED-TRIAL; DISEASE STATUS; THERAPYMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/49165

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item